This site is intended for healthcare professionals

Travere Therapeutics announces successful outcome from Type A meeting with FDA

Read time: 1 mins
Last updated:9th Sep 2021
Published:9th Sep 2021
Travere Therapeutics, Inc> announced a successful outcome from the Company’s Type A meeting with the FDA in which alignment was reached on the Company’s plan to submit additional estimated glomerular filtration rate (eGFR) data from the ongoing pivotal Phase III DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) to support an application for accelerated approval in 2022.
Condition: Focal Segmental Glomerulosclerosis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest